L3VLUP
ProSign in

SUPN · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

SUPNVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • SUPN
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterSUPNVRTX
Q3 20203 holders, $49m31 holders, $21.9bn
Q4 20201 holders, $47m30 holders, $18.4bn
Q1 20211 holders, $46m31 holders, $15.4bn
Q2 20212 holders, $48m30 holders, $12.7bn
Q3 20213 holders, $40m35 holders, $10.1bn
Q4 20212 holders, $36m28 holders, $12.4bn
Q1 20224 holders, $62m23 holders, $16.1bn
Q2 20224 holders, $62m25 holders, $18.1bn
Q3 20225 holders, $75m22 holders, $18.4bn
Q4 20225 holders, $53m28 holders, $18.4bn
Q1 20233 holders, $55m26 holders, $21.4bn
Q2 20232 holders, $45m27 holders, $24.7bn
Q3 20231 holders, $40m33 holders, $24.3bn
Q4 20231 holders, $40m32 holders, $28.6bn
Q1 20243 holders, $91m31 holders, $29.8bn
Q2 20241 holders, $45m29 holders, $33.4bn
Q3 20243 holders, $61m27 holders, $33.5bn
Q4 20243 holders, $75m26 holders, $28.5bn
Q1 20253 holders, $54m21 holders, $35.4bn
Q2 20253 holders, $80m21 holders, $32.3bn
Q3 20256 holders, $244m22 holders, $25.9bn
Q4 20259 holders, $381m26 holders, $31.8bn
Q1 20268 holders, $399m25 holders, $31.8bn
Q2 20266 holders, $299m26 holders, $34.6bn
SUPN

Supernus Pharmaceuticals Inc

Holders
9
Reported value
$381m
Buyers
17
Sellers
14

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only SUPN (6)

Brevan Howard Capital Management LP, Caxton Associates LLP, ExodusPoint Capital Management LP, Freestone Grove Partners LP, PDT Partners LLC, Point72 Asset Management LP

Only VRTX (23)

AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →